InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,352.96
(
-0.02%
)
US TECH 100
18,558.00
(
0.13%
)
Dow Jones
38,886.17
(
0.20%
)
Brent Oil
79.78
(
-0.13%
)
Bitcoin
71,216.98
(
0.64%
)
Post# of 252095
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119784
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 181001

Thursday, 03/24/2016 8:13:09 AM

Thursday, March 24, 2016 8:13:09 AM

Post# of 252095
PTLA -28%/AH on Betrixaban failure in APEX study (as I predicted on numerous occasions):

http://finance.yahoo.com/news/portola-pharmaceuticals-announces-topline-results-110000380.html

PTLA’s contention that Betrixaban was “uniquely suited” to treat patients in this indication, where other FXa inhibitors had failed, never rang true, IMO.

Moreover, there was a pretty big red flag in the APEX trial design, as noted in #msg-105048954.

CC at 8:30am ET.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up